Your browser doesn't support javascript.
loading
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study.
Higuchi, Mitsunori; Inomata, Sho; Yamaguchi, Hikaru; Saito, Takuro; Suzuki, Hiroyuki.
Afiliação
  • Higuchi M; Department of Thoracic Surgery, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Tanisawa, Kawahigashi, Aizuwakamatsu, 969-3492, Japan. higuchi@fmu.ac.jp.
  • Inomata S; Department of Thoracic Surgery, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Tanisawa, Kawahigashi, Aizuwakamatsu, 969-3492, Japan.
  • Yamaguchi H; Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Saito T; Department of Surgery, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
  • Suzuki H; Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
J Cardiothorac Surg ; 18(1): 235, 2023 Jul 20.
Article em En | MEDLINE | ID: mdl-37475037
ABSTRACT

BACKGROUND:

The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached.

METHODS:

We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA-IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients' clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan-Meier method.

RESULTS:

Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2-9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively).

CONCLUSIONS:

Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article